Logo image
Back
High-dose cyclophosphamide for refractory autoimmune hemolytic anemia
Journal article   Open access   Peer reviewed

High-dose cyclophosphamide for refractory autoimmune hemolytic anemia

Victor M Moyo, Douglas Smith, Isadore Brodsky, Pamela Crilley, Richard J Jones, Robert A Brodsky and David B Smith
Blood, v 100(2), pp 704-706
15 Jul 2002
DOI: https://doi.org/10.1182/blood-2002-01-0087
PMID: 12091370
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1182/blood-2002-01-0087View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze),  Open

Abstract

Adult Anemia, Hemolytic, Autoimmune - drug therapy Child Cyclophosphamide - administration & dosage Cyclophosphamide - toxicity Female Follow-Up Studies Humans Male Middle Aged Remission Induction - methods Salvage Therapy Treatment Outcome
High-dose cyclophosphamide, without stem cell rescue, has been used successfully to treat aplastic anemia and other autoimmune disorders. To determine the safety and efficacy of high-dose cyclophosphamide among patients with severe refractory autoimmune hemolytic anemia, we treated 9 patients with cyclophosphamide (50 mg. kg(-1). d(-1) for 4 days) who had failed a median of 3 (range, 1-7) other treatments. The median hemoglobin before treatment was 6.7 g/dL (range, 5-10 g/dL). The median time to reach an absolute neutrophil count of 500/microL or greater was 16 days (range, 12-18 days). Six patients achieved complete remission (normal untransfused hemoglobin for age and sex), and none have relapsed after a median follow-up of 15 months (range, 4-29 months). Three patients achieved and continue in partial remission (hemoglobin at least 10 g/dL without transfusion support). High-dose cyclophosphamide was well tolerated and induced durable remissions in patients with severe refractory autoimmune hemolytic anemia.

Metrics

5 Record Views
85 citations in Web of Science
101 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Hematology
Logo image